Fintech– 0

Biogen to present new lupus drug data

Globenewswire·March 19, 2026 at 11:30 AM

Biogen is set to present new late-breaking Phase 2 AMETHYST study data for its drug litifilimab at the 2026 American Academy of Dermatology Annual Meeting. The presentation will focus on the safety and efficacy of litifilimab in treating cutaneous lupus erythematosus. This upcoming data release is anticipated to provide further insights into the drug's potential as a treatment for this autoimmune condition.

Biogen to present new lupus drug data

OpenAI, Google refine AI commerce strategies

Nevada bars Kalshi from offering event contracts

Federal Reserve orders SVB collapse review

Centralizing Treasury Operations Offers Key Benefits